IQVIA Holdings Inc. (NYSE:IQV) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213 On March 9, 2026, TD Cowen upgraded its rating on IQVIA Holdings Inc. (NYSE:IQV) from Hold to Buy. Along with the rating upgrade, the firm also raised its price target on the stock from $174 to $213. The company is anticipated to remain resilient against AI-driven revenue headwinds, according to TD Cowen analysts. It furthe ...

Core Insights - The emergence of AI is seen as a significant opportunity for the company, contributing positively to both revenue and margin expansion over time [2] - The company’s proprietary data and domain expertise are highlighted as key assets that are being recognized in the context of AI [2] Group 1 - The company is currently operating 70 agentic modules, indicating a strong focus on AI integration and development [1] - There is a need to clarify how initial demand for AI solutions will translate into business growth [1] Group 2 - The narrative surrounding AI has led to misunderstandings about the company's data offerings, emphasizing the importance of its proprietary data in the pharmaceutical sector [2]

Summary of IQVIA FY Conference Call - March 12, 2026 Company Overview - **Company**: IQVIA (NYSE:IQV) - **Industry**: Life Sciences, Clinical Research Organizations (CROs) Key Points AI Integration and Impact - AI is viewed as a net positive for IQVIA, enhancing both revenue and margin expansion over time [14][18] - IQVIA possesses the most robust data set in the industry with 150,000 live data feeds, which is crucial for building effective AI models [15] - The company has transitioned from a traditional data provider to a more integrated partner for pharma companies, with 19 out of the top 20 pharma already using IQVIA's AI agents [18] - The roadmap includes deploying over 500 AI agents by 2027, with a focus on both clinical and commercial applications [18] Demand Environment - The demand environment is improving, with healthy metrics in RFPs and qualified pipelines, indicating a more optimistic outlook for 2026 compared to previous years [78][80] - The book-to-bill ratio is not forecasted due to its volatility, but the overall sentiment from clients is more positive [76][80] Biotech Strategy - The "See More, Win More" strategy is aimed at early engagement with biotech clients, which has been successful in revitalizing the business segment [88][98] - Biotech funding is robust, and companies are increasingly taking their developments deeper into clinical phases, which is beneficial for IQVIA [99][100] Margins and Operational Efficiency - IQVIA has a strong track record of expanding margins, with only two instances of contraction in the past nine years [122] - The recent margin contraction was primarily due to non-operational factors, and operationally, the company remains sound [123] - Productivity programs, including automation and AI, are key to maintaining and improving margins [124] Acquisition Strategy - IQVIA is focusing on expanding its capabilities in drug discovery, having acquired Specifica for large molecule drug discovery and looking for small molecule discovery businesses [115][118] - The acquisition of Charles River's non-core assets aligns with IQVIA's strategy to enhance its discovery capabilities [115][116] Client Engagement and Market Position - The company emphasizes the importance of early engagement with clients, particularly in the biotech sector, to build trust and secure contracts [96][98] - IQVIA's proprietary data and expertise are seen as significant advantages over competitors, especially in the context of AI [14][15] Additional Insights - The conversation highlighted the evolving nature of client relationships, with pharma companies increasingly seeking IQVIA's expertise rather than relying solely on internal capabilities [27][36] - The historical context of AI's impact on the CRO industry was discussed, drawing parallels to past technological shifts that ultimately led to new service offerings and growth [62][65] This summary encapsulates the critical insights from the IQVIA FY Conference Call, focusing on the company's strategic direction, market dynamics, and operational performance.

Core Insights - IQVIA Holdings Inc. is recognized as one of the best affordable growth stocks to buy now, with an Outperform rating and a price target of $221 set by RBC Capital [1][2] Group 1: Company Progress and Capabilities - The company is making significant strides in clinical trial activity and is expected to benefit from advancements in contract research organization and data analytics capabilities [2] - IQVIA holds over 64 petabytes of data and has established relationships with large pharmaceutical companies, which is seen as a critical differentiator in the market [2][3] Group 2: Technological Integration and Acquisitions - The integration and adoption of artificial intelligence in life sciences are anticipated to further enhance the company's outlook [3] - IQVIA has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories, which includes five sites for in vitro discovery services [3] Group 3: Industry Positioning - IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, focusing on improving healthcare outcomes through data, technology, and human expertise [4]

Core Insights - IQVIA Holdings Inc. is a healthcare research services provider with a market cap of $30.3 billion, offering analytics, technology solutions, and clinical research services to the life sciences industry [1] - The company is classified as a large-cap stock, emphasizing its size and influence in the diagnostics and research industry, with a global presence in over 100 countries [2] Financial Performance - IQVIA's stock has declined 27.7% from its 52-week high of $247.05, with an 18.1% drop over the past three months, underperforming the Nasdaq Composite's 3.7% losses [3] - Year-to-date, shares of IQV have fallen 20.8%, and over the past 52 weeks, they have decreased by 6.8%, significantly underperforming the Nasdaq's YTD losses of 2.4% and 24.7% returns over the last year [5] - The company reported Q4 results with an adjusted EPS of $3.42, exceeding expectations, and revenue of $4.4 billion, also surpassing forecasts [8] Market Position and Competition - Despite its strengths, IQVIA faces challenges such as margin compression and concerns regarding the sustainability of its gains, with operating margins declining due to changes in product mix and pass-through revenue growth [7] - In the competitive diagnostics and research sector, Agilent Technologies has shown resilience with a 14.3% loss year-to-date, but has underperformed IQVIA over the past 52 weeks with a 7.9% decline [9]

Core Viewpoint - The discussion centers around the company's positioning in the AI sector and its strengths related to artificial intelligence, highlighting a potential gap between market perception and reality [1]. Group 1: AI Positioning - The company is recognized for its AI-oriented strengths, which may not be fully appreciated in the current market landscape [1]. - There is an ongoing debate regarding the perception versus reality of the company's capabilities in AI, indicating a need for clearer communication of its strengths [1].

Upgrades - TD Cowen upgraded Iqvia (IQV) to Buy from Hold with a price target of $213, increased from $174, citing no expected revenue headwinds from AI [2] - Wolfe Research upgraded Brinker (EAT) to Outperform from Peer Perform with a price target of $184, noting that the Chili's unit has "earned value credibility" and traffic has outperformed [2] - Scotiabank upgraded Verizon (VZ) to Outperform from Sector Perform with a price target of $54.50, up from $50.25, after positive management meetings indicating strong momentum in subscriber loading and cost improvements [3] - Argus upgraded AutoZone (AZO) to Buy from Hold with a price target of $4,325, driven by expectations of positive year-over-year profit growth starting in Q3 after two quarters of negative earnings growth [4] - Rothschild & Co Redburn upgraded GE Vernova (GEV) to Buy from Sell with a price target of $1,100, up from $560, due to stronger than expected demand and margins in power and utilities [4] Downgrades - Wolfe Research downgraded Starbucks (SBUX) to Peer Perform from Outperform without a price target, indicating a need for evidence of sustained execution despite emerging positive signs [5] - William Blair downgraded Talkspace (TALK) to Market Perform from Outperform without a price target, following the announcement of its acquisition by Universal Health Services (UHS) for $5.25 per share, totaling $835 million [5] - TD Cowen downgraded Western Alliance (WAL) to Hold from Buy with a price target of $83, citing decreased investor tolerance for future credit events despite idiosyncratic exposures [5] - Bernstein downgraded Brown-Forman (BF.B) to Market Perform from Outperform with a price target of $29, down from $37.50, due to anticipated margin pressures from rising costs of barreled whiskey [5] - Citizens downgraded Marriott Vacations (VAC) to Market Perform from Outperform without a price target, suggesting the board should have considered strategic alternatives given a 60% stock decline over the previous CEO's tenure [5]

Company Overview - IQVIA Holdings Inc. (NYSE:IQV) is a contract research organization (CRO) that provides clinical research and data analytics to the healthcare and life sciences industries, assisting pharmaceutical and biotech companies in managing clinical trials, providing laboratory services, and tracking sales and patient engagement [2]. Market Performance - IQVIA was noted as the ninth-worst performing stock in the S&P 500, with a decline of 22.3% [1]. - Despite a solid earnings report in early February, the company provided a weaker than expected full-year forecast [1]. Industry Context - The CRO sector, including IQVIA, has been impacted by the AI displacement trade, which is viewed as an unfair assessment of the industry [1]. - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to IQVIA [3].

Investment Rating - The report emphasizes a favorable investment outlook for emerging biopharmaceutical companies (EBPs) that leverage technology-driven commercialization strategies, suggesting a shift away from traditional models [6][11]. Core Insights - The healthcare system is increasingly led by digital-savvy decision-makers who demand faster, more relevant, and personalized information, fundamentally altering the commercialization rules in the pharmaceutical market [5][10]. - EBPs have a unique opportunity to maximize asset value through self-commercialization, unencumbered by legacy infrastructures, allowing them to adopt streamlined, technology-driven business models [6][9]. - The report highlights the importance of modern data management and technology as foundational elements for enabling EBPs to navigate the evolving market landscape effectively [40][56]. Summary by Sections Executive Summary - The report outlines a transformative era in the biopharmaceutical industry, driven by technological advancements and changing customer expectations, which necessitates a reevaluation of traditional commercialization pathways [5][10]. New Era of Commercialization - The compression of asset lifecycles and rising evidence thresholds are challenging traditional commercialization approaches, requiring innovators to adapt quickly to capture market potential [14][15]. - The emergence of diverse and demanding customers, alongside the rise of digital-native decision-makers, is reshaping the landscape of healthcare interactions [15][22]. Golden Opportunities for EBP - EBPs can leap to advanced, technology-enabled business models that are agile and capable of personalized engagement, meeting the evolving demands of the market [9][11]. - The report discusses three strategic options for EBPs to unlock asset value: self-commercialization, co-commercialization with partners, or licensing assets to third parties [30][31][32]. Foundations of New Models - A technology-driven business model is essential for EBPs, focusing on speed, agility, and precision in operations, supported by a robust data architecture [35][40]. - The report emphasizes the need for EBPs to build a high-level data blueprint to enhance flexibility and responsiveness in their commercialization efforts [43][41]. Technology-Enabled Commercialization - The integration of advanced technologies, such as AI and data analytics, is crucial for EBPs to streamline processes and enhance customer interactions [49][50]. - The report highlights the potential of AI-driven agents to transform customer engagement by providing personalized experiences and improving operational efficiency [50][52]. Full-Service Outsourcing - The report advocates for a full-service outsourcing model that allows EBPs to minimize risks and operational complexities while maximizing local market presence and knowledge [63][67]. - Effective governance structures are essential for seamless collaboration with partners, ensuring clarity in responsibilities and enhancing operational efficiency [70][71].

IQVIA Holdings Inc. (NYSE:IQV) is one of the most undervalued AI stocks to buy now. With significant analyst and hedge fund sentiment, alongside a low forward price-to-earnings (PE) ratio, IQVIA Holdings Inc. (NYSE:IQV) secures a spot on our list of the most undervalued AI stocks to buy now. Following the company’s fourth-quarter earnings release, analysts at Mizuho and Truist revise their valuation models on IQVIA Holdings Inc. (NYSE:IQV). Incorporating the company’s Q4 performance, Mizuho lowered its ...